Drivers for change in the management of prostate cancer - Guidelines and new treatment techniques

BJU International

Volumn 109, Issue SUPPL. 6, 2012, Pages 33-41

  Wolff, J M ^a   Mason, M ^b  

^a Department of Urology   (Germany)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Guidelines; Prostate cancer; Radiotherapy; Surgery

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABARELIX; ABIRATERONE; CABAZITAXEL; DEGARELIX; DENOSUMAB; DOCETAXEL; GONADORELIN AGONIST; HYDROCORTISONE; LEUPRORELIN; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; TUMOR MARKER; ZOLEDRONIC ACID;

BONE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COMPARATIVE EFFECTIVENESS; CRYOABLATION; DIGITAL RECTAL EXAMINATION; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HIGH INTENSITY FOCUSED ULTRASOUND; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; ION THERAPY; LAPAROSCOPIC SURGERY; LASER THERMOTHERAPY; METASTASIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; REVIEW;

ANDROGEN ANTAGONISTS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CRYOSURGERY; CYTOTOXINS; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; HYPERTHERMIA, INDUCED; IONS; MALE; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PRACTICE GUIDELINES AS TOPIC; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; ROBOTICS;

EID: 84862157102     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11218.x     Document Type: Review

References (55)

1. McCormack JP, Loewen P. Adding " value " to clinical practice guidelines. Can Fam Physician 2007; 53: 1326-7
2. National Institute for Health and Clinical Excellence. Clinical guideline 58. Prostate cancer. Diagnosis and treatment. Developed by the National Collaborating Centre for Cancer. February 2008. Available from: http://www.nice.org.uk/nicemedia/live/11924/39626/39626.pdf [Accessed January 2012]
3. Leitlinienprogramm Onkologie. Interdisziplin ä re Leitlinie der Qualit ät S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Version 2.0-1. Aktualisierung 2011. Available from http://www.degro.org/dav/html/leitlinien/LLPCA.pdf Accessed January 2012
4. Aus G, Abbou CC, Pacik D et al.; EAU Working Group on Oncological Urology. EAU guidelines on PCa. Eur Urol 2001; 40: 97-101
5. Heidenreich A, Bolla M, Joniau S et al. European Association of Urology. Guidelines on Prostate Cancer. April 2010. Available from: http://www.uroweb. org/gls/pdf/08-Prostate-Cancer.pdf [ Accessed January 2012 ]
6. Heidenreich A, Bellmunt J, Bolla M et al. European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
7. Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-83
8. Heidenreich A, Aus G, Abbou CC et al. European Association of Urology. Guidelines on Prostate Cancer. March 2007. Available from: http://www.uroweb. org/fileadmin/user-upload/Guidelines/07-Prostate-Cancer-2007.pdf [Accessed January 2012]
9. Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80
10. Heidenreich A, Bolla M, Joniau S et al. European Association of Urology. Guidelines on prostate cancer. January 2011: Available from http://www.uroweb. org/gls/pdf/08-Prostate-Cancer.pdf. Accessed December 2011
11. Food and Drug Administration. FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. 2010. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm. [ Accessed January 2012 ]
12. Crawford ED, Tombal B, Miller K et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 2011; 186: 889-97
13. Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 1290-5
14. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010; 105: 648-51
15. Heidenreich A, Bolla M, Joniau S et al. European Association of Urology. Guidelines on Prostate Cancer. March 2009. Available from: http://www.uroweb. org/fileadmin/tx-eauguidelines/2009/Full/Prostate-Cancer.pdf [ Accessed January 2012 ]
16. Shore N, Mason M, De Reijke T. New developments in castrate-resistant prostate cancer. BJU Int (in press) (this supplement)
17. Scher HI, Fizazi K, Saad F et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol 2012; 30: 2012 (suppl 5; abstr LBA1)
18. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
19. Kelly WK, Scher HI, Mazurmdar M et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory PCa. J Clin Oncol 1993; 11: 607-15
20. Smith DC, Dunn RL, Strawderman MS et al. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormonere-fractory PCa. J Clin Oncol 1998; 16: 1835-43
21. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory PCa. J Clin Oncol 2006; 24: 3089-94
22. Kantoff PW, Schuetz T, Blumenstein BA et al. Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant PCa (mCRPC). J Clin Oncol 2009; 27: 15s (suppl; abstract #5013)
23. Scher HI, Jia X, de Bono JS et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant PCa: a reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10: 233-9
24. Helo P, Cronin AM, Danila DC et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory PCa: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 2009; 55: 765-73
25. Goodman OB Jr, Fink LM, Symanowski JT et al. Circulating tumor cells in patients with castration-resistant PCa baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev 2009; 18: 1904-13
26. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant PCa based on risk factors for PSA decline and survival. Eur J Cancer 2010; 46: 517-25
27. Coelho RF, Rocco B, Patel MB et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol 2010; 24: 2003-15
28. Menon M, Bhandari M, Gupta N et al. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. Eur Urol 2010; 58: 838-46
29. Intuitive Surgical Inc. Da Vinci® prostatectomy. 2012. Available from: http://www.davincisurgery.com/urology/urology-procedures/ radicalprostatectomy/ [Accessed 21 March 2012]
30. Roswell Park Cancer Institute. Robot-assisted radical prostatectomy. Available from: http://www.roswellpark.org/cancer/prostate/treatment/ robotassisted-radical-prostatectomy [Accessed January 2012]
31. Asimakopoulos AD, Pereira Fraga CT, Annino F, Pasqualetti P, Calado AA, Mugnier C. Randomized comparison between laparoscopic and robot-assisted nerve-sparing radical prostatectomy. J Sex Med 2011; 8: 1503-12
32. Murphy DG, Bjartell A, Ficarra V et al. Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol 2010; 57: 735-46
33. Lindner U, Trachtenberg J, Lawrentschuk N. Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol 2010; 7: 562-71
34. Onik G. Image-guided prostate cryosurgery: state of the art. Cancer Control 2001; 8: 522-31
35. Donnelly BJ, Saliken JC, Brasher PM et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010; 116: 323-30
36. Chin JL, Ng CK, Touma NJ et al. Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B. Prostate Cancer Prostatic Dis 2008; 11: 40-5
37. Lindner U, Weersink RA, Haider MA et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol 2009; 182: 1371-7
38. Lepor H. Vascular targeted photodynamic therapy for localized prostate cancer. Rev Urol 2008; 10: 254-61
39. Preise D, Scherz A, Salomon Y. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP). Photochem Photobiol Sci 2011; 10: 681-8
40. Trachtenberg J, Bogaards A, Weersink RA et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 2007; 178: 1974-9
41. Trachtenberg J, Weersink RA, Davidson SR et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 2008; 102: 556-62
42. Betrouni N, Lopes R, Puech P, Colin P, Mordon S. A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11. Phys Med Biol 2011; 56: 4771-83
43. Lukka H, Waldron T, Chin J et al.; Genitourinary Cancer Disease Site Group of Cancer Care Ontario ' s Program in Evidence-Based Care. High-intensity focused ultrasound for prostate cancer: a systematic review. Clin Oncol (R Coll Radiol) 2011; 23: 117-27
44. Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol 2010; 58: 803-15
45. Biagioli MC, Hoffe SE. Emerging technologies in prostate cancer radiation therapy: improving the therapeutic window. Cancer Control 2010; 17: 223-32
46. Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. H ealth Technol Assess 2010; 14: 1-108, iii-iv
47. Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after shortcourse intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 904-12
48. Vora SA, Wong WW, Schild SE, Ezzell GA, Halyard MY. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1053-8
49. Cahlon O, Zelefsky MJ, Shippy A et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008; 71: 330-7
50. Ling CC, Yorke E, Fuks Z. From IMRT to IGRT: frontierland or neverland? Radiother Oncol 2006; 78: 119-22
51. Shah AP, Chen SS, Strauss JB et al. A dosimetric analysis comparing treatment of low-risk prostate cancer with tomotherapy versus static field intensity modulated radiation therapy. Am J Clin Oncol 2009; 32: 460-6
52. Zietman AL, Bae K, Slater JD et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010; 28: 1106-11
53. Talcott JA, Rossi C, Shipley WU et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 2010; 303: 1046-53
54. Ishikawa H, Tsuji H, Kamada T et al.; Working Group for Genitourinary Tumors. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol 2006; 81: 57-64
55. Heidenreich A, Bastian PJ, Bellmunt J et al. European Association of Urology. Guidelines on prostate cancer. February 2012: Available from: http://www.uroweb.org/gls/pdf/08-Prostate-Cancer.pdf. Accessed March 2012